| 1 | Expertenkonsensus: Meningokokkenprophylaxe in der Therapie neurologischer Erkrankungen mit Komplementinhibitoren | 0.7 | 3 | Citations (PDF) |
| 2 | Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade | 6.7 | 34 | Citations (PDF) |
| 3 | Association of cytokine proteins with disease activity in NMOSD participants receiving inebilizumab treatment | 1.3 | 0 | Citations (PDF) |
| 4 | Matching-adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-term Effectiveness (P10-14.006) | 1.0 | 0 | Citations (PDF) |
| 5 | Association of Cytokine Proteins with Disease Activity in Neuromyelitis Optica Spectrum Disorder Participants Receiving Inebilizumab Treatment (S32.005) | 1.0 | 0 | Citations (PDF) |
| 6 | Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness
z
Scores | 6.7 | 10 | Citations (PDF) |
| 7 | Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders | 6.7 | 6 | Citations (PDF) |
| 8 | Heterophoria in multiple sclerosis patients: a proof of principle cross-sectional study | 4.9 | 0 | Citations (PDF) |
| 9 | Eculizumab Use in Neuromyelitis Optica Spectrum Disorders | 1.0 | 31 | Citations (PDF) |
| 10 | Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease | 6.7 | 9 | Citations (PDF) |
| 11 | Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review | 3.5 | 34 | Citations (PDF) |
| 12 | Myelinating Co-Culture as a Model to Study Anti-NMDAR Neurotoxicity | 4.4 | 3 | Citations (PDF) |
| 13 | Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort | 6.7 | 23 | Citations (PDF) |
| 14 | Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis | 3.4 | 205 | Citations (PDF) |
| 15 | Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab | 6.7 | 10 | Citations (PDF) |
| 16 | Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder | 6.3 | 38 | Citations (PDF) |
| 17 | Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation | 3.5 | 14 | Citations (PDF) |
| 18 | Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders | 6.3 | 23 | Citations (PDF) |
| 19 | AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder | 2.2 | 33 | Citations (PDF) |
| 20 | CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy | 6.7 | 16 | Citations (PDF) |
| 21 | Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic Taoism | 10.8 | 13 | Citations (PDF) |
| 22 | Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population | 4.9 | 10 | Citations (PDF) |
| 23 | Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease | 1.0 | 34 | Citations (PDF) |
| 24 | Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients | 9.0 | 137 | Citations (PDF) |
| 25 | The degree of cortical plasticity correlates with cognitive performance in patients with Multiple Sclerosis | 1.5 | 17 | Citations (PDF) |
| 26 | Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders | 6.7 | 135 | Citations (PDF) |
| 27 | Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab | 6.3 | 29 | Citations (PDF) |
| 28 | Thinking outside the box: non-canonical targets in multiple sclerosis | 79.7 | 109 | Citations (PDF) |
| 29 | Changing Perspectives from Oxidative Stress to Redox Signaling—Extracellular Redox Control in Translational Medicine | 5.8 | 30 | Citations (PDF) |
| 30 | Longitudinal Retinal Changes in MOGAD | 6.6 | 53 | Citations (PDF) |
| 31 | Neuromyelitis-optica-Spektrum-Erkrankung: Pathogene Antikörper als Auslöser und Angriffspunkt 2022, , | | 0 | Citations (PDF) |
| 32 | Worldwide Incidence and Prevalence of Neuromyelitis Optica | 1.0 | 300 | Citations (PDF) |
| 33 | Anti-CD20 therapies and pregnancy in neuroimmunologic disorders | 6.7 | 76 | Citations (PDF) |
| 34 | Long‐term adherence and response to botulinum toxin in different indications | 3.7 | 27 | Citations (PDF) |
| 35 | Pain, depression, and quality of life in adults with MOG‐antibody–associated disease | 3.5 | 39 | Citations (PDF) |
| 36 | Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD | 3.9 | 17 | Citations (PDF) |
| 37 | Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis | 6.7 | 33 | Citations (PDF) |
| 38 | Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder | 6.7 | 36 | Citations (PDF) |
| 39 | Von der Neuromyelitis optica zur Neuromyelitis-optica-Spektrum-Erkrankung: vom klinischen Syndrom zur Klassifikation | 0.8 | 3 | Citations (PDF) |
| 40 | Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker | 6.6 | 132 | Citations (PDF) |
| 41 | APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies | 1.0 | 216 | Citations (PDF) |
| 42 | Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder | 6.7 | 79 | Citations (PDF) |
| 43 | Artificial intelligence extension of the OSCAR‐IB criteria | 3.7 | 44 | Citations (PDF) |
| 44 | Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis | 6.7 | 22 | Citations (PDF) |
| 45 | Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue | 2.3 | 11 | Citations (PDF) |
| 46 | Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19 | 6.7 | 101 | Citations (PDF) |
| 47 | Retinal Optical Coherence Tomography in Neuromyelitis Optica | 6.7 | 82 | Citations (PDF) |
| 48 | Myelin-oligodendrocyte glycoprotein antibody-associated disease | 17.9 | 495 | Citations (PDF) |
| 49 | C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD | 2.3 | 31 | Citations (PDF) |
| 50 | SPMS-Therapie bleibt eine Herausforderung | 0.0 | 0 | Citations (PDF) |
| 51 | Targeting B Cells to Modify MS, NMOSD, and MOGAD | 6.7 | 55 | Citations (PDF) |
| 52 | Targeting B cells to modify MS, NMOSD, and MOGAD | 6.7 | 43 | Citations (PDF) |
| 53 | Relapse-independent multiple sclerosis progression under natalizumab | 3.6 | 39 | Citations (PDF) |
| 54 | Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal | 2.3 | 3 | Citations (PDF) |
| 55 | Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study | 17.9 | 31 | Citations (PDF) |
| 56 | Retinal Structure and Function as a Predictor of Long-Term Visual Outcomes: A Post Hoc Analysis of RENEW and RENEWED (1945) | 1.0 | 1 | Citations (PDF) |
| 57 | Serum neurofilament light chain | 6.7 | 44 | Citations (PDF) |
| 58 | Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany | 1.4 | 9 | Citations (PDF) |
| 59 | Occipital repetitive transcranial magnetic stimulation does not affect multifocal visual evoked potentials | 2.1 | 2 | Citations (PDF) |
| 60 | Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients | 9.0 | 139 | Citations (PDF) |
| 61 | Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients | 9.0 | 67 | Citations (PDF) |
| 62 | Retinal layers and visual conductivity changes in a case series of microangiopathic ischemic stroke patients | 1.9 | 4 | Citations (PDF) |
| 63 | Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis | 2.3 | 7 | Citations (PDF) |
| 64 | Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO) | 1.9 | 18 | Citations (PDF) |
| 65 | Ocrelizumab zur Behandlung der Multiplen Sklerose | 0.8 | 3 | Citations (PDF) |
| 66 | Retinal Changes After Posterior Cerebral Artery Infarctions Display Different Patterns of the Nasal und Temporal Sector in a Case Series | 2.3 | 6 | Citations (PDF) |
| 67 | Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders | 6.7 | 59 | Citations (PDF) |
| 68 | Capillary microscopy in Europeans with idiopathic Moyamoya angiopathy | 1.6 | 1 | Citations (PDF) |
| 69 | Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders | 1.0 | 47 | Citations (PDF) |
| 70 | The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis | 4.6 | 3 | Citations (PDF) |
| 71 | Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report | 1.9 | 21 | Citations (PDF) |
| 72 | Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosisBrain, 2020, 143, 1127-1142 | 8.4 | 39 | Citations (PDF) |
| 73 | Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium | 8.0 | 55 | Citations (PDF) |
| 74 | B-Zell-Depletion 2.0: Bei NMOSD ist Anti-CD19-Immuntherapie wirksam | 0.0 | 0 | Citations (PDF) |
| 75 | Rituximab wirkt NMOSD-Schüben entgegen | 0.0 | 0 | Citations (PDF) |
| 76 | Confirmed Progression independent of Relapse Activity in Multiple Sclerosis Patients under long-term Natalizumab Treatment. (1372) | 1.0 | 0 | Citations (PDF) |
| 77 | Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data | 1.9 | 19 | Citations (PDF) |
| 78 | Drug Treatment of Clinically Isolated Syndrome | 6.3 | 19 | Citations (PDF) |
| 79 | No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease | 2.3 | 4 | Citations (PDF) |
| 80 | Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases | 2.9 | 7 | Citations (PDF) |
| 81 | Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis | 9.0 | 42 | Citations (PDF) |
| 82 | Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial | 62.1 | 691 | Citations (PDF) |
| 83 | Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study | 1.0 | 50 | Citations (PDF) |
| 84 | Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients | 3.4 | 36 | Citations (PDF) |
| 85 | Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells | 1.9 | 27 | Citations (PDF) |
| 86 | Misdiagnoses and delay of diagnoses in Moyamoya angiopathy—a large Caucasian case series | 3.4 | 36 | Citations (PDF) |
| 87 | Meningitis gone viral: description of the echovirus wave 2013 in Germany | 2.6 | 13 | Citations (PDF) |
| 88 | Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects | 3.8 | 9 | Citations (PDF) |
| 89 | Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 – continuity and change | 3.8 | 50 | Citations (PDF) |
| 90 | Monoclonal Antibodies for Multiple Sclerosis: An Update | 6.2 | 28 | Citations (PDF) |
| 91 | Managing Risks with Immune Therapies in Multiple Sclerosis | 2.8 | 21 | Citations (PDF) |
| 92 | Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study | 2.3 | 24 | Citations (PDF) |
| 93 | High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy | 1.0 | 131 | Citations (PDF) |
| 94 | Therapie der multiplen Sklerose: Medikamentöse Ansätze zur Remyelinisierung in Prüfung 2019, , | | 0 | Citations (PDF) |
| 95 | Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. (P5.2-071) | 1.0 | 0 | Citations (PDF) |
| 96 | Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis | 3.8 | 32 | Citations (PDF) |
| 97 | Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge | 3.5 | 48 | Citations (PDF) |
| 98 | Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model | 9.0 | 46 | Citations (PDF) |
| 99 | Bewirkt das Antihistaminikum Clemastin eine Remyelinisierung? | 0.0 | 0 | Citations (PDF) |
| 100 | Cladribin-Tabletten | 0.8 | 4 | Citations (PDF) |
| 101 | Shifting borders, crossing boundaries: The case of combined central and peripheral demyelination | 3.9 | 5 | Citations (PDF) |
| 102 | Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy | 3.7 | 7 | Citations (PDF) |
| 103 | Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential | 6.3 | 46 | Citations (PDF) |
| 104 | Racial differences in neuromyelitis optica spectrum disorder | 1.0 | 174 | Citations (PDF) |
| 105 | Apheresis therapies for NMOSD attacks | 6.7 | 233 | Citations (PDF) |
| 106 | Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment | 3.9 | 20 | Citations (PDF) |
| 107 | Predictors of response to opicinumab in acute optic neuritis | 3.7 | 24 | Citations (PDF) |
| 108 | Neuroimmunologische Register in Deutschland | 0.2 | 3 | Citations (PDF) |
| 109 | Diagnose der Multiplen Sklerose: Revision der McDonald-Kriterien 2017 | 0.8 | 16 | Citations (PDF) |
| 110 | Alterations of the outer retina in non‐arteritic anterior ischaemic optic neuropathy detected using spectral‐domain optical coherence tomography | 2.9 | 8 | Citations (PDF) |
| 111 | Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial | 17.9 | 257 | Citations (PDF) |
| 112 | Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response | 6.3 | 149 | Citations (PDF) |
| 113 | Iron‐sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microgliaGlia, 2017, 65, 1521-1534 | 5.0 | 46 | Citations (PDF) |
| 114 | Paraneoplastic limbic encephalitis with SOX1 and PCA2 antibodies and relapsing neurological symptoms in an adolescent with Hodgkin lymphoma | 1.8 | 16 | Citations (PDF) |
| 115 | Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis | 17.9 | 568 | Citations (PDF) |
| 116 | Fulminant intramedullary spinal cord sarcoidosis | 2.2 | 2 | Citations (PDF) |
| 117 | Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension | 3.4 | 65 | Citations (PDF) |
| 118 | Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS | 6.7 | 47 | Citations (PDF) |
| 119 | Influence of female sex and fertile age on neuromyelitis optica spectrum disorders | 3.9 | 79 | Citations (PDF) |
| 120 | Infectious risk stratification in multiple sclerosis patients receiving immunotherapy | 3.7 | 17 | Citations (PDF) |
| 121 | Cellular composition of peripheral blood mononuclear cells during 4 years long-term treatment with fingolimod (P5.364) | 1.0 | 1 | Citations (PDF) |
| 122 | Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis | 3.8 | 45 | Citations (PDF) |
| 123 | Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial—study protocol | 1.9 | 51 | Citations (PDF) |
| 124 | Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica | 6.3 | 290 | Citations (PDF) |
| 125 | Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients | 1.9 | 15 | Citations (PDF) |
| 126 | Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis | 14.1 | 25 | Citations (PDF) |
| 127 | MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin | 9.0 | 398 | Citations (PDF) |
| 128 | MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome | 9.0 | 826 | Citations (PDF) |
| 129 | MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients | 9.0 | 246 | Citations (PDF) |
| 130 | Diagnostic criteria for Susac syndrome | 6.3 | 226 | Citations (PDF) |
| 131 | MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome | 9.0 | 234 | Citations (PDF) |
| 132 | Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy | 9.0 | 26 | Citations (PDF) |
| 133 | Placebo-controlled study in neuromyelitis optica—Ethical and design considerations | 3.9 | 70 | Citations (PDF) |
| 134 | Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation | 9.0 | 87 | Citations (PDF) |
| 135 | Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses | 6.6 | 413 | Citations (PDF) |
| 136 | Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study | 17.9 | 324 | Citations (PDF) |
| 137 | Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study | 3.4 | 61 | Citations (PDF) |
| 138 | Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis | 6.7 | 54 | Citations (PDF) |
| 139 | Evidence That the Anti-LINGO-1 Monoclonal Antibody BIIB033 Protects Against Multifocal Visual Evoked Potential Amplitude Loss in the Fellow Eye of Subjects with Unilateral Acute Optic Neuritis (I10.009) | 1.0 | 1 | Citations (PDF) |
| 140 | Evidence That the Anti-LINGO-1 Monoclonal Antibody BIIB033 Protects Against Multifocal Visual Evoked Potential Amplitude Loss in the Fellow Eye of Subjects with Unilateral Acute Optic Neuritis (S49.006) | 1.0 | 0 | Citations (PDF) |
| 141 | Natalizumab restores aberrant miRNAexpression profile in multiple sclerosis and reveals a critical role for miR‐20b | 3.7 | 75 | Citations (PDF) |
| 142 | Redox-regulated fate of neural stem progenitor cells | 2.0 | 39 | Citations (PDF) |
| 143 | Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder | 17.6 | 234 | Citations (PDF) |
| 144 | Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder | 17.6 | 62 | Citations (PDF) |
| 145 | Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations | 2.2 | 11 | Citations (PDF) |
| 146 | Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany | 2.6 | 34 | Citations (PDF) |
| 147 | IFNβ secreted by microglia mediates clearance of myelin debris in CNS autoimmunity | 5.0 | 108 | Citations (PDF) |
| 148 | Genome-wide significant association with seven novel multiple sclerosis risk loci | 3.8 | 37 | Citations (PDF) |
| 149 | Gamma-aminobutyric acid receptor agonists, aquaporin-4, and neuromyelitis optica: a potential link | 0.7 | 6 | Citations (PDF) |
| 150 | Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography | 1.0 | 29 | Citations (PDF) |
| 151 | Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography | 1.0 | 61 | Citations (PDF) |
| 152 | Update on biomarkers in neuromyelitis optica | 6.7 | 115 | Citations (PDF) |
| 153 | Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis | 3.9 | 100 | Citations (PDF) |
| 154 | Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis | 6.0 | 41 | Citations (PDF) |
| 155 | BAX inhibitor-1 is a Ca2+ channel critically important for immune cell function and survival | 13.3 | 34 | Citations (PDF) |
| 156 | Safety and Tolerability of Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis: the RENEW trial (P7.203) | 1.0 | 0 | Citations (PDF) |
| 157 | Pregnancy does not prevent degeneration of retinal axons in multiple sclerosis (P5.206) | 1.0 | 0 | Citations (PDF) |
| 158 | Subtle retinal pathology in amyotrophic lateral sclerosis | 3.7 | 71 | Citations (PDF) |
| 159 | Photoreceptor layer thinning in Parkinsonian syndromes | 4.6 | 14 | Citations (PDF) |
| 160 | Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate | 9.0 | 26 | Citations (PDF) |
| 161 | Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab | 1.9 | 22 | Citations (PDF) |
| 162 | Biopsie bei tumorverdächtiger spinaler Raumforderung: Fallstrick Neuromyelitis optica | 0.8 | 2 | Citations (PDF) |
| 163 | Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study | 9.0 | 119 | Citations (PDF) |
| 164 | Assessment of microRNA-related SNP effects in the 3′ untranslated region of the IL22RA2 risk locus in multiple sclerosis | 1.0 | 19 | Citations (PDF) |
| 165 | Visual evoked potentials in neuromyelitis optica and its spectrum disorders | 3.9 | 56 | Citations (PDF) |
| 166 | MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosisBrain, 2013, 136, 1778-1782 | 8.4 | 65 | Citations (PDF) |
| 167 | Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica | 17.6 | 115 | Citations (PDF) |
| 168 | Characteristics of Susac syndrome: a review of all reported cases | 28.6 | 348 | Citations (PDF) |
| 169 | Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk | 3.8 | 35 | Citations (PDF) |
| 170 | Glutaredoxin regulates vascular development by reversible glutathionylation of sirtuin 1 | 7.5 | 97 | Citations (PDF) |
| 171 | Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome | 3.9 | 145 | Citations (PDF) |
| 172 | Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS) | 3.4 | 537 | Citations (PDF) |
| 173 | Optical Coherence Tomography in Parkinsonian Syndromes: The Impact of Different Techniques of Manual Segmentation (IN4-1.008) | 1.0 | 0 | Citations (PDF) |
| 174 | Optical Coherence Tomography in Parkinsonian Syndromes: The Impact of Different Techniques of Manual Segmentation (P06.079) | 1.0 | 0 | Citations (PDF) |
| 175 | Retinal Neurodegeneration in Wilson's Disease Revealed by Spectral Domain Optical Coherence Tomography (P06.008) | 1.0 | 0 | Citations (PDF) |
| 176 | Demyelination reduces brain parenchymal stiffness quantified in vivo by magnetic resonance elastography | 7.5 | 221 | Citations (PDF) |
| 177 | Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography | 3.9 | 120 | Citations (PDF) |
| 178 | Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica | 6.8 | 299 | Citations (PDF) |
| 179 | Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects: Figure 1 | 3.8 | 33 | Citations (PDF) |
| 180 | An emboligenic pulmonary abscess leading to ischemic stroke and secondary brain abscess | 1.9 | 9 | Citations (PDF) |
| 181 | p57kip2 regulates glial fate decision in adult neural stem cells | 3.1 | 33 | Citations (PDF) |
| 182 | Testing for antibodies to human aquaporin-4 by ELISA: Sensitivity, specificity, and direct comparison with immunohistochemistry | 2.1 | 66 | Citations (PDF) |
| 183 | Optical Coherence Tomography in Parkinsonian Syndromes | 2.3 | 165 | Citations (PDF) |
| 184 | Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients | 9.0 | 702 | Citations (PDF) |
| 185 | Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy | 2.6 | 106 | Citations (PDF) |
| 186 | Cladribine as a therapeutic option in multiple sclerosis | 2.6 | 13 | Citations (PDF) |
| 187 | Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS | 2.3 | 58 | Citations (PDF) |
| 188 | Retinal Neurodegeneration in Wilson’s Disease Revealed by Spectral Domain Optical Coherence Tomography | 2.3 | 50 | Citations (PDF) |
| 189 | Electrostatically stabilized magnetic nanoparticles – an optimized protocol to label murine T cells for in vivo MRI | 2.3 | 15 | Citations (PDF) |
| 190 | The complex world of oligodendroglial differentiation inhibitors | 6.6 | 124 | Citations (PDF) |
| 191 | Modulation of adult hippocampal neurogenesis during myelin‐directed autoimmune neuroinflammation | 5.0 | 57 | Citations (PDF) |
| 192 | Therapie der Multiplen Sklerose mit monoklonalen Antikörpern: aktualisierte Empfehlungen zum Umgang mit Natalizumab im Rahmen eines Expertenmeetings | 0.2 | 5 | Citations (PDF) |
| 193 | Primary retinal pathology in multiple sclerosis as detected by optical coherence tomographyBrain, 2011, 134, e193-e193 | 8.4 | 63 | Citations (PDF) |
| 194 | Alemtuzumab: eine weitere Chance zur Therapie der Multiplen Sklerose | 0.8 | 1 | Citations (PDF) |
| 195 | Independent replication of STAT3 association with multiple sclerosis risk in a large German case–control sample | 1.0 | 22 | Citations (PDF) |
| 196 | Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation | 2.3 | 87 | Citations (PDF) |
| 197 | Cladribin | 0.8 | 4 | Citations (PDF) |
| 198 | Oral therapies for multiple sclerosis: are we there yet? | 17.9 | 7 | Citations (PDF) |
| 199 | Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress | 33.6 | 542 | Citations (PDF) |
| 200 | Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis | 9.8 | 90 | Citations (PDF) |
| 201 | Fingolimod is a potential novel therapy for multiple sclerosis | 28.6 | 178 | Citations (PDF) |
| 202 | Neue therapeutische Konzepte bei der Multiplen Sklerose | 0.1 | 0 | Citations (PDF) |
| 203 | Cytotoxic CD8+T Cell–Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death | 3.7 | 88 | Citations (PDF) |
| 204 | Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis | 1.0 | 60 | Citations (PDF) |
| 205 | Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis | 6.6 | 162 | Citations (PDF) |
| 206 | Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system | 33.0 | 128 | Citations (PDF) |
| 207 | MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study | 3.6 | 35 | Citations (PDF) |
| 208 | Beyond blood brain barrier breakdown – in vivodetection of occult neuroinflammatory foci by magnetic nanoparticles in high field MRI | 9.0 | 47 | Citations (PDF) |
| 209 | Development of oral cladribine for the treatment of multiple sclerosis | 3.4 | 42 | Citations (PDF) |
| 210 | Sirt1 contributes critically to the redox-dependent fate of neural progenitors | 16.3 | 432 | Citations (PDF) |
| 211 | Roles of the kallikrein/kinin system in the adaptive immune system | 4.2 | 31 | Citations (PDF) |
| 212 | Autoregulation of Th1-mediated inflammation by twist1 | 9.3 | 105 | Citations (PDF) |
| 213 | Neues zu Pathogenese, Diagnostik und Therapie der Neuromyelitis optica | 0.2 | 3 | Citations (PDF) |
| 214 | Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis | 2.3 | 114 | Citations (PDF) |
| 215 | Neuronal Damage in Brain Inflammation | 6.8 | 232 | Citations (PDF) |
| 216 | Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery | 2.1 | 23 | Citations (PDF) |
| 217 | Impact of HMG-CoA reductase inhibition on brain pathology | 11.4 | 59 | Citations (PDF) |
| 218 | The role of TRAIL/TRAIL receptors in central nervous system pathology | 5.8 | 63 | Citations (PDF) |
| 219 | Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets | 2.3 | 43 | Citations (PDF) |
| 220 | TRAIL limits excessive host immune responses in bacterial meningitis | 10.6 | 64 | Citations (PDF) |
| 221 | Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica | 8.0 | 192 | Citations (PDF) |
| 222 | The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases | 9.8 | 341 | Citations (PDF) |
| 223 | Rezidivierendes reversibles posteriores Leukenzephalopathiesyndrom unter Chemotherapie mit Cisplatin und 5-Fluorouracil | 0.8 | 7 | Citations (PDF) |
| 224 | Death Ligands and Autoimmune Demyelination | 4.3 | 40 | Citations (PDF) |
| 225 | Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion | 1.3 | 23 | Citations (PDF) |
| 226 | New aspects regarding mechanisms of tissue damage in the course of autoimmune demyelination | 0.5 | 0 | Citations (PDF) |
| 227 | Frequency of blood CX3CR1‐positive natural killer cells correlates with disease activity in multiple sclerosis patients | 0.6 | 91 | Citations (PDF) |
| 228 | Indolamine 2,3‐dioxygenase is expressed in the CNS and down‐regulates autoimmune inflammation | 0.6 | 273 | Citations (PDF) |
| 229 | Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL | 11.0 | 220 | Citations (PDF) |
| 230 | Multiple Sklerose – weit mehr als eine Entmarkungskrankheit | 0.2 | 0 | Citations (PDF) |
| 231 | Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study | 3.9 | 49 | Citations (PDF) |
| 232 | Direct Impact of T Cells on Neurons Revealed by Two-Photon Microscopy in Living Brain Tissue | 3.7 | 136 | Citations (PDF) |
| 233 | Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI studyBrain, 2004, 127, 111-119 | 8.4 | 208 | Citations (PDF) |
| 234 | Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis | 0.6 | 328 | Citations (PDF) |
| 235 | Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis | 2.3 | 25 | Citations (PDF) |
| 236 | Systemic IFN-β treatment induces apoptosis of peripheral immune cells in MS patients | 2.3 | 45 | Citations (PDF) |
| 237 | TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis | 62.1 | 197 | Citations (PDF) |
| 238 | Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin | 9.3 | 278 | Citations (PDF) |
| 239 | Activation of Microglial Poly(ADP-Ribose)-Polymerase-1 by Cholesterol Breakdown Products during Neuroinflammation | 9.3 | 152 | Citations (PDF) |
| 240 | Elevated Bcl-XL levels correlate with T cell survival in multiple sclerosis | 2.3 | 31 | Citations (PDF) |
| 241 | Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis | 2.3 | 42 | Citations (PDF) |
| 242 | Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells — implications for multiple sclerosis1This work was supported by grants from the DFG, the Hertie-Stiftung and the DMSG.1 | 2.3 | 5 | Citations (PDF) |
| 243 | Apoptose bei multipler Sklerose | 0.8 | 2 | Citations (PDF) |
| 244 | Remyelinisierungsförderung als zukünftiges Therapieprinzip der Multiplen Sklerose? | 0.8 | 0 | Citations (PDF) |
| 245 | Therapeutic approaches in adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A review of current evidence | 7.1 | 2 | Citations (PDF) |
| 246 | Prescription Drug Use in NMOSD: A Population-Based Study in Greece with Estimation of National Disease Administrative Prevalence | 2.5 | 0 | Citations (PDF) |
| 247 | OCT-Based Differentiation of First Acute Optic Neuritis | 6.7 | 1 | Citations (PDF) |
| 248 | Cognitive training, exercise training or combined training? A comparative effectiveness research study on subjective and objective cognitive outcomes in multiple sclerosis | 3.4 | 0 | Citations (PDF) |
